Advertisement

Picture Consultech GmbH Secure Funding with RnD Grants v7 650x100px
Document › Details

Idorsia Ltd.. (6/20/23). "Press Release: Idorsia Has Secured Bridge Financing in the Amount of CHF 75 Million (Ad hoc announcement pursuant to Art. 53 LR)". Allschwil.

Organisations Organisation Idorsia Ltd. (SIX: IDIA)
  Group Idorsia (Group)
  Organisation 2 PERSON
Products Product small-molecule drug
  Product 2 drug development
Persons Person Clozel, Jean-Paul (Idorsia 20403 CEO + Co-Founder before Actelion)
  Person 2 Weiss, Andrew C. (Idorsia 201706– SVP + Head Investor Relations + Corporate Communications before Actelion)
     


Idorsia Ltd (SIX: IDIA) today announced that it has secured bridge financing in the amount of CHF 75 million to extend the company’s cash runway until the end of July and in the meantime allow the completion of the recently announced prospective strategic transaction for its Asia Pacific (ex-China) operations, which is subject to completion of satisfactory due diligence and legal documentation. The credit facility has been provided by Jean-Paul Clozel, CEO, Member of the Board of Directors and Idorsia’s largest shareholder.


Notes to the editor


About Idorsia

Idorsia Ltd is reaching out for more – We have more ideas, we see more opportunities and we want to help more patients. In order to achieve this, we will develop Idorsia into a leading biopharmaceutical company, with a strong scientific core.

Headquartered near Basel, Switzerland – a European biotech-hub – Idorsia is specialized in the discovery, development and commercialization of small molecules to transform the horizon of therapeutic options. Idorsia has a 20-year heritage of drug discovery, a broad portfolio of innovative drugs in the pipeline, an experienced team of professionals covering all disciplines from bench to bedside, and commercial operations in Europe, Japan, and the US – the ideal constellation for bringing innovative medicines to patients.

Idorsia was listed on the SIX Swiss Exchange (ticker symbol: IDIA) in June 2017 and has over 1,300 highly qualified specialists dedicated to realizing our ambitious targets.


For further information, please contact

Andrew C. Weiss
Senior Vice President, Head of Investor Relations & Corporate Communications
Idorsia Pharmaceuticals Ltd, Hegenheimermattweg 91, CH-4123 Allschwil
+41 58 844 10 10
investor.relations@idorsia.com
media.relations@idorsia.com
www.idorsia.com


The above information contains certain "forward-looking statements", relating to the company's business, which can be identified by the use of forward-looking terminology such as "estimates", "believes", "expects", "may", "are expected to", "will", "will continue", "should", "would be", "seeks", "pending" or "anticipates" or similar expressions, or by discussions of strategy, plans or intentions. Such statements include descriptions of the company's investment and research and development programs and anticipated expenditures in connection therewith, descriptions of new products expected to be introduced by the company and anticipated customer demand for such products and products in the company's existing portfolio. Such statements reflect the current views of the company with respect to future events and are subject to certain risks, uncertainties and assumptions. Many factors could cause the actual results, performance or achievements of the company to be materially different from any future results, performances or achievements that may be expressed or implied by such forward-looking statements. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated or expected.

   
Record changed: 2024-05-05

Advertisement

Picture Berlin Partner Top News Healthtech Company Mika 650x200px

More documents for Idorsia (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Advertisement

Picture Berlin Partner Top News Healthtech Company Mika 650x300px




» top